tetano
Editor, Senior Moderator
Life (Basel)
. 2022 Mar 14;12(3):420.
doi: 10.3390/life12030420.
Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience
Massimo Franchini[SUP] 1 [/SUP], Claudia Glingani[SUP] 1 [/SUP], Giuseppe De Donno[SUP] 2 [/SUP], Giuseppe Lucchini[SUP] 3 [/SUP], Massimiliano Beccaria[SUP] 2 [/SUP], Massimo Amato[SUP] 4 [/SUP], Gian Paolo Castelli[SUP] 5 [/SUP], Leonardo Bianciardi[SUP] 6 [/SUP], Mauro Pagani[SUP] 7 [/SUP], Marco Ghirardini[SUP] 8 [/SUP], Giuseppe Puma[SUP] 9 [/SUP], Barbara Presciuttini[SUP] 7 [/SUP], Maria Teresa Costantino[SUP] 10 [/SUP], Marilena Frigato[SUP] 10 [/SUP], Verena Crosato[SUP] 11 [/SUP], Giorgio Tiecco[SUP] 11 [/SUP], Alice Mulè[SUP] 11 [/SUP], Dorothea Angela Papalia[SUP] 11 [/SUP], Francesco Inglese[SUP] 2 [/SUP], Fabio Spreafico[SUP] 2 [/SUP], Martina Garuti[SUP] 2 [/SUP], Antonietta Pecoriello[SUP] 2 [/SUP], Giulia Cervi[SUP] 2 [/SUP], Graziana Greco[SUP] 2 [/SUP], Vanni Galavotti[SUP] 2 [/SUP], Tiziana Santini[SUP] 8 [/SUP], Angela Berselli[SUP] 5 [/SUP], Carlo Montalto[SUP] 5 [/SUP], Riccardo Bertoletti[SUP] 12 [/SUP], Simona Aurelia Bellometti[SUP] 12 [/SUP], Enrico Capuzzo[SUP] 1 [/SUP], Dario Benazzi[SUP] 4 [/SUP], Gianpaolo Grisolia[SUP] 13 [/SUP], Fabio Pajola[SUP] 12 [/SUP], Raffaello Stradoni[SUP] 14 [/SUP], Matteo Zani[SUP] 1 [/SUP], Adriano Verzola[SUP] 15 [/SUP], Vito Codeluppi[SUP] 16 [/SUP], Silvia Vesentini[SUP] 16 [/SUP], Elisa Bellocchio[SUP] 16 [/SUP], Marco Candini[SUP] 16 [/SUP], Giorgina Ambrosi[SUP] 16 [/SUP], Francesca Carandina[SUP] 16 [/SUP], Cleante Scarduelli[SUP] 17 [/SUP], Albino Reggiani[SUP] 18 [/SUP], Salvatore Casari[SUP] 9 [/SUP], On Behalf Of Convalescent Plasma Study Group
Affiliations
Abstract
In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80-320). Their median age was 68 years (IQR, 56-78 years), and 62% were males. At enrollment, 55% of patients had an increased body mass index (BMI), and 25.6% had at least three comorbidities. The 28-day crude mortality rate was 12.6% (51/405). Young age (<68 years), mild disease (admission to low-intensity departments) and early treatment (<7 days from symptoms onset) with high nAb titer (≥320) CCP were found as independently associated with a favorable response to CCP treatment. No safety concerns were recorded, with a rate of CCP-related adverse reactions (all of mild intensity) of 1.3%. In our real-life experience, the first in the western world, early administration of high-titer CCP was a safe and effective treatment for hospitalized COVID-19 patients.
Keywords: COVID-19; convalescent plasma; mortality; safety.
. 2022 Mar 14;12(3):420.
doi: 10.3390/life12030420.
Convalescent Plasma for Hospitalized COVID-19 Patients: A Single-Center Experience
Massimo Franchini[SUP] 1 [/SUP], Claudia Glingani[SUP] 1 [/SUP], Giuseppe De Donno[SUP] 2 [/SUP], Giuseppe Lucchini[SUP] 3 [/SUP], Massimiliano Beccaria[SUP] 2 [/SUP], Massimo Amato[SUP] 4 [/SUP], Gian Paolo Castelli[SUP] 5 [/SUP], Leonardo Bianciardi[SUP] 6 [/SUP], Mauro Pagani[SUP] 7 [/SUP], Marco Ghirardini[SUP] 8 [/SUP], Giuseppe Puma[SUP] 9 [/SUP], Barbara Presciuttini[SUP] 7 [/SUP], Maria Teresa Costantino[SUP] 10 [/SUP], Marilena Frigato[SUP] 10 [/SUP], Verena Crosato[SUP] 11 [/SUP], Giorgio Tiecco[SUP] 11 [/SUP], Alice Mulè[SUP] 11 [/SUP], Dorothea Angela Papalia[SUP] 11 [/SUP], Francesco Inglese[SUP] 2 [/SUP], Fabio Spreafico[SUP] 2 [/SUP], Martina Garuti[SUP] 2 [/SUP], Antonietta Pecoriello[SUP] 2 [/SUP], Giulia Cervi[SUP] 2 [/SUP], Graziana Greco[SUP] 2 [/SUP], Vanni Galavotti[SUP] 2 [/SUP], Tiziana Santini[SUP] 8 [/SUP], Angela Berselli[SUP] 5 [/SUP], Carlo Montalto[SUP] 5 [/SUP], Riccardo Bertoletti[SUP] 12 [/SUP], Simona Aurelia Bellometti[SUP] 12 [/SUP], Enrico Capuzzo[SUP] 1 [/SUP], Dario Benazzi[SUP] 4 [/SUP], Gianpaolo Grisolia[SUP] 13 [/SUP], Fabio Pajola[SUP] 12 [/SUP], Raffaello Stradoni[SUP] 14 [/SUP], Matteo Zani[SUP] 1 [/SUP], Adriano Verzola[SUP] 15 [/SUP], Vito Codeluppi[SUP] 16 [/SUP], Silvia Vesentini[SUP] 16 [/SUP], Elisa Bellocchio[SUP] 16 [/SUP], Marco Candini[SUP] 16 [/SUP], Giorgina Ambrosi[SUP] 16 [/SUP], Francesca Carandina[SUP] 16 [/SUP], Cleante Scarduelli[SUP] 17 [/SUP], Albino Reggiani[SUP] 18 [/SUP], Salvatore Casari[SUP] 9 [/SUP], On Behalf Of Convalescent Plasma Study Group
Affiliations
- PMID: 35330170
- DOI: 10.3390/life12030420
Abstract
In Winter 2020, Italy, and in particular the Lombardy region, was the first country in the Western hemisphere to be hit by the COVID-19 pandemic. Plasma from individuals recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first therapeutic tool adopted to counteract the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In this retrospective cohort study, we report the experience of the city hospital of Mantua, Lombardy region, on the compassionate use of CCP in patients hospitalized for severe COVID-19. Between April 2020 and April 2021, 405 consecutive COVID-19 patients received 657 CCP units with a median anti-SARS-CoV-2 neutralizing antibody (nAb) titer of 160 (interquartile range (IQR), 80-320). Their median age was 68 years (IQR, 56-78 years), and 62% were males. At enrollment, 55% of patients had an increased body mass index (BMI), and 25.6% had at least three comorbidities. The 28-day crude mortality rate was 12.6% (51/405). Young age (<68 years), mild disease (admission to low-intensity departments) and early treatment (<7 days from symptoms onset) with high nAb titer (≥320) CCP were found as independently associated with a favorable response to CCP treatment. No safety concerns were recorded, with a rate of CCP-related adverse reactions (all of mild intensity) of 1.3%. In our real-life experience, the first in the western world, early administration of high-titer CCP was a safe and effective treatment for hospitalized COVID-19 patients.
Keywords: COVID-19; convalescent plasma; mortality; safety.